Vaccination therapy combined with chemotherapy for recurrent pancreatic cancer patients

进行了使用用HSP 105肽脉冲的树突细胞的疫苗接种疗法的I期试验。入选标准为具有表达HSP 105和HLA-A2或HLA-A24的癌组织的晚期/复发性癌症患者。使用5 × 106个DC细胞/处理（步骤1）、1 × 107个DC细胞/处理（步骤2）和2 × 107个DC细胞/处理（步骤3）应用剂量增加方案。第2步中，所有患者均出现DTH反应。1例肿瘤缓解为SD，2例为PD。在步骤3中，4名胰腺癌患者是候选者，但只有1名患者接受治疗，因为其他3名患者的PS恶化。DTH反应也有，但肿瘤反应为PD。

A phase I trial of vaccination therapy using dendrite cells pulsed with HSP105 peptide was conducted. Inclusion criteria were patients with advanced/recurrent cancer with cancer tissue expressing HSP105 and with HLA-A2 or HLA-A24. Dosing-up protocols were applied using 5x106 DC cells/tretament (step 1), 1X107 DC cells/treatment (step 2), and 2X107 DC cells/ treatment (step 3).In the step 1, CD8 positive T cells specific for HSP105 were not recognized. In the step 2, DTH reaction was found in all the patients. Tumor response was SD in 1, and PD in 2. In the step 3, 4 patients with pancreatic cancer were the candidates, but only one patient received the therapy, as PS deteriorated in the other 3 patients. DTH reaction was also be found, but the tumor response was PD.